OTCM
ARSUF
Market cap1.95bUSD
Feb 01, Last price
18.06
Name
Fagron NV
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.
Related entities
Subsidiaries (4)
Fagron B.V.
FAGRON CAPITAL
Dr. Kulich Pharma, s.r.o.
FAGRON a.s.
Key people
Independent Chairman of the Board - Representing AHOK BV · since 2017
Rafael Padilla
Chief Executive Officer, Executive Director · since 2018
Karin de Jong
Chief Financial Officer, Executive Director · since 2017
Vera Bakker
Chief Operations Officer · since 2022
Kostas Kouloridas
Area Leader, EMEA · since 2024
Geraldino Neder
Area Leader, Latin America · since 2022
Andrew Pulido
Area Leader, North America · since 2021
Johan Verlinden
Head - Legal and M&A · since 2021
Non-Executive Director · since 2023
Non-Executive Independent Director · since 2022
Neeraj Sharma
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2019
Els Vandecandelaere
Non-Executive Independent Director - Permanent Representative of Els Vandecandelaere LLC · since 2022
Headquarters & legal address
Venecoweg 20A
Nazareth, VOV 9810
BE
Nazareth, VOV 9810
BE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||